International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Decoding the Anti-Inflammatory Potential of Turmeric Phytochemicals Through Molecular Docking

Aditya Jayprakash Mundada[1], Syeda Afifa[2]

[1] Student, Department of Pharmacy, Sayali Charitable Trust's College of Pharmacy
[2] Assistant Professor, Department of pharmacy, Sayali Charitable Trust's College of Pharmacy

Abstract:
Chronic inflammation is a primary driver of debilitating diseases, traditionally managed with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that often present severe gastrointestinal and renal toxicities. This study investigates the therapeutic potential of Curcumin, a natural bioactive polyphenol, as a safer, selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme using an in-silico computer-aided drug design (CADD) approach. Molecular docking simulations were performed using AutoDock Vina to evaluate the thermodynamic binding affinity and intermolecular interactions between Curcumin (PubChem CID: 969516) and the human COX-2 receptor (PDB ID: 5IKR).
The simulation identified a highly stable lead binding pose with an affinity of -6.74 kcal/mol, indicating a spontaneous and thermodynamically favorable interaction. Residue mapping confirmed that Curcumin specifically targets the hydrophobic catalytic channel, forming key non-covalent interactions with critical residues such as ARG120 and TYR355. This suggests a competitive inhibitory mechanism that obstructs the entry of arachidonic acid. Furthermore, offline ADMET profiling via OSIRIS DataWarrior verified that Curcumin strictly adheres to Lipinski's Rule of Five with zero violations and exhibits a benign toxicological profile with no mutagenic, tumorigenic, reproductive, or irritant risks. These computational findings validate Curcumin as a potent, safe, and biologically tolerated natural lead compound for the management of chronic inflammation, providing a strong structural rationale for its traditional use and future clinical formulation.

Keywords: Molecular Docking, Curcumin, Cyclooxygenase-2 (COX-2), Anti-inflammatory Agents, Computer-Aided Drug Design (CADD), ADMET Profiling, AutoDock Vina, Lipinski's Rule of Five.

CHAPTER 1: INTRODUCTION

The search for effective therapeutic agents to manage pain and inflammation has been a cornerstone of pharmaceutical research for decades. In the modern era, the focus has shifted from synthetic drug development toward "In-silico" (computational) drug discovery. This approach allows researchers to explore the medicinal potential of natural phytochemicals with high precision, reduced costs, and ethical efficiency. The current study focuses on **Curcumin**, the primary bioactive constituent of Turmeric, and its molecular interaction with the **COX-2 enzyme**—a key mediator in the human inflammatory pathway. By

utilizing molecular docking, this research aims to provide a structural basis for the traditional use of curcumin as a potent anti-inflammatory agent.

1.1 The Biological Mechanism of Inflammation

In the field of medical science, **inflammation** is often described as the body's "alarm system." It is a fundamental, protective immune response triggered by various harmful stimuli, such as physical injury, bacterial infection, or chemical irritation. When the body detects damage, it sends white blood cells and specialized chemicals to the site to begin the healing process. [1]

Fig1. The Inflammatory response



However, a major challenge in pharmacy arises when this "alarm" fails to turn off. While **acute inflammation** is helpful and short-term, **chronic inflammation** is persistent and destructive. Over time, this prolonged state of high alert begins to damage healthy tissues and organs. In modern healthcare, chronic inflammation is recognized as the underlying cause of several debilitating conditions, including:

- **Rheumatoid Arthritis:** A condition where the immune system mistakenly attacks the joints.
- **Osteoarthritis:** The gradual wear and tear of joint cartilage over time.
- **Cardiovascular Diseases:** Where persistent inflammation contributes to the hardening of arteries (atherosclerosis).

Understanding this transition from "protective" to "harmful" inflammation is the critical first step in designing effective therapeutic interventions. [2]

1.2 The Role of Cyclooxygenase-2 (COX-2)

Within the human body, the production of inflammatory mediators is controlled by a family of enzymes known as **Cyclooxygenases (COX)**. These enzymes are responsible for converting arachidonic acid, which is released from damaged cell membranes, into **prostaglandins**. Prostaglandins are the potent

chemical messengers that directly signal the nervous system to perceive pain and trigger the physical symptoms of swelling and heat.

In pharmaceutical science, we differentiate between two primary isoforms of this enzyme:



Fig2. Isoform Differentiation

- **COX-1 (Constitutive):** This is the "housekeeping" enzyme. It is present in most tissues under normal conditions and performs essential protective functions, such as maintaining the gastric mucosal lining and supporting platelet aggregation.
- **COX-2 (Induced):** This is the "target" enzyme for your study. Unlike COX-1, it is usually absent in healthy cells but is rapidly "switched on" or induced by inflammatory stimuli. It is the primary driver of the excessive prostaglandin production seen in chronic diseases. [3]

The central goal of modern drug design is to achieve **Selective Inhibition**. We aim to identify a molecule, such as Curcumin, that can specifically block the COX-2 enzyme to stop pain while leaving the protective COX-1 enzyme untouched to avoid damaging the stomach.

1.3 Limitations of Conventional NSAIDs

Currently, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Aspirin, Ibuprofen, and Diclofenac, represent the gold standard for managing pain and inflammation. While these drugs are undeniably effective, their long-term therapeutic use is severely restricted by a well-documented profile of Adverse Drug Reactions (ADRs). The clinical challenge facing modern pharmacy is that traditional NSAIDs are **non-selective**; they act as "blindfold inhibitors." They succeed in blocking the inflammation-causing COX-2 enzyme, but they simultaneously inhibit the "good" COX-1 enzyme, which is essential for homeostatic functions.

This non-selective inhibition of COX-1 leads to a significant reduction in protective prostaglandins in the stomach, which can result in:

- **Gastric Toxicity:** The breakdown of the stomach's mucus lining, leading to severe side effects like gastritis, peptic ulcers, and gastrointestinal bleeding.

- **Renal Stress:** Impaired blood flow to the kidneys, increasing the risk of fluid retention and acute renal failure.
- **Cardiovascular Risks:** An imbalance in pro-thrombotic and anti-thrombotic mediators, which can increase the risk of heart attacks. [4]

The clear existence of these toxicities has pushed contemporary pharmaceutical research toward a "targeted therapy" approach—finding **Selective COX-2 Inhibitors** that offer robust anti-inflammatory relief without the accompanying gastrointestinal or renal damage.



Fig 3. Mechanisms of Conventional NSAID Toxicity

1.4 Curcumin: A Natural Therapeutic Lead

In the search for safer anti-inflammatory agents, the pharmaceutical industry has returned to traditional ethnobotany. **Curcumin** (diferuloylmethane) is the primary bioactive polyphenol extracted from the rhizome of the *Curcuma longa* (Turmeric) plant. While turmeric has been a staple of Ayurvedic and Traditional Chinese Medicine for over 2,500 years, modern pharmacology has only recently begun to decode its molecular "poly-pharmacology."



Fig 4. Chemical Structure of Curcumin and its source (curcuma longa)

Chemically, curcumin is a symmetric molecule consisting of two aromatic rings joined by an unsaturated seven-carbon chain. This unique chemical scaffold allows it to interact with multiple signaling pathways simultaneously. Most importantly, curcumin has demonstrated a natural ability to downregulate the expression and activity of the **COX-2 enzyme**.

Unlike synthetic drugs, curcumin is categorized as "Generally Recognized as Safe" (GRAS) by the FDA. However, its clinical application is limited by poor aqueous solubility and rapid metabolism. By utilizing **Computer-Aided Drug Design (CADD)** and molecular docking, we can precisely visualize how curcumin fits into the COX-2 binding pocket. This "In-silico" evidence is crucial for developing improved, more bioavailable formulations of this ancient phytochemical. [5]

1.5 Rationale of the Study

The transition toward **Computer-Aided Drug Design (CADD)** represents a significant technological leap in pharmaceutical sciences. Traditionally, drug discovery was a "trial and error" process involving the synthesis of thousands of compounds followed by extensive animal testing—a process that could take over a decade and cost billions of dollars.

The rationale for utilizing an *In-silico* molecular docking approach in this study is based on three primary pillars:

- **Cost and Time Efficiency:** Traditional laboratory screening is resource-intensive. Computational simulations allow for the rapid screening of phytochemicals, significantly reducing the time required to identify a "lead" compound.
- **Ethical Compliance (3Rs Principle):** Modern science emphasizes the **3Rs**: *Replacement, Reduction, and Refinement* of animal testing. By using computers to predict binding, we reduce the need for unnecessary animal models in the early stages of research.
- **Molecular Precision:** Docking provides a "microscopic" view of the atom-to-atom interactions between Curcumin and COX-2 that is impossible to see in a standard test tube experiment. This high level of detail allows us to predict the efficacy of a drug before it is even synthesized. [6]



Fig 5. Comparison of Traditional vs. Computer-Aided Drug Discovery (CADD)

2.2 Structural Biology of the COX-2 Enzyme (PDB ID: 5IKR)

The success of a molecular docking study depends heavily on the structural integrity of the target protein. For this research, the **Human Cyclooxygenase-2 (COX-2)** enzyme was selected, identified by its Protein Data Bank (PDB) entry code: **5IKR**. This specific crystal structure was chosen because it represents the human isoform of the enzyme at a high resolution (2.34 Å), allowing for precise atomic-level observations of the binding pocket.

Structurally, COX-2 is a homodimeric protein, meaning it consists of two identical subunits. Each subunit contains three functional domains: an N-terminal epidermal growth factor (EGF)-like domain, a membrane-binding domain, and a large C-terminal catalytic domain. The catalytic domain houses the **cyclooxygenase active site**, which is a long, hydrophobic channel. It is within this specific channel that arachidonic acid is normally converted into prostaglandins. The 5IKR structure is particularly valuable as it was co-crystallized with an inhibitor, providing a clear map of the "active site" where Curcumin is expected to bind.

CHAPTER 2: LITERATURE REVIEW

2.1 Pharmacological Profile of Curcumin

Extensive research over the past two decades has validated Curcumin as a "multi-target" therapeutic agent. Unlike synthetic drugs that usually target a single receptor, Curcumin interacts with a variety of inflammatory signaling molecules, transcription factors, and enzymes.

Studies have shown that Curcumin's anti-inflammatory effects are primarily attributed to its ability to inhibit the activation of **Nuclear Factor-kappa B (NF-κB)**, which acts as the "master switch" for inflammation in human cells. By blocking this switch, Curcumin naturally reduces the production of various inflammatory cytokines and the **COX-2 enzyme**. Furthermore, clinical trials have indicated that Curcumin can provide symptomatic relief in patients with inflammatory conditions (like osteoarthritis) that is comparable to pharmaceutical-grade NSAIDs, but with a significantly higher safety profile. [7]



Fig 6. Multi-targeted Anti-inflammatory Mechanism of Curcumin

2.2 Structural Biology of the COX-2 Enzyme (PDB ID: 5IKR)

The success of a molecular docking study depends heavily on the structural integrity of the target protein. For this research, the **Human Cyclooxygenase-2 (COX-2)** enzyme was selected, identified by its Protein Data Bank (PDB) entry code: **5IKR**. This specific crystal structure was chosen because it represents the human isoform of the enzyme at a high resolution (2.34 Å), allowing for precise atomic-level observations of the binding pocket.

Structurally, COX-2 is a homodimeric protein, meaning it consists of two identical subunits. Each subunit contains three functional domains: an N-terminal epidermal growth factor (EGF)-like domain, a membrane-binding domain, and a large C-terminal catalytic domain. The catalytic domain houses the **cyclooxygenase active site**, which is a long, hydrophobic channel. It is within this specific channel that arachidonic acid is normally converted into prostaglandins. The 5IKR structure is particularly valuable as it was co-crystallized with an inhibitor, providing a clear map of the "active site" where Curcumin is expected to bind. [8]



Fig 7. Three-Dimensional Architecture of Human COX-2 (PDB ID: 5IKR)

2.3 Fundamentals of Molecular Docking Theory

Molecular docking is a computational optimization strategy used to predict the preferred orientation of a small molecule (the ligand) when bound to a second, larger molecule (the receptor/protein). In pharmaceutical research, this process is frequently described through the **"Lock and Key"** hypothesis. The algorithm systematically explores the binding pocket of the enzyme to find the most energetically favorable fit for the drug molecule.



Fig 8. Schematic Representation of the Molecular Docking Process and Scoring

The docking process relies on two critical components:

- **Search Algorithm:** Since molecules are not rigid, the algorithm explores the "conformational space" of the ligand. It rotates and bends the Curcumin molecule into thousands of different spatial arrangements (poses) to determine which one fits most precisely inside the COX-2 active site.
- **Scoring Function:** Once a potential pose is identified, the software applies a mathematical formula to calculate the **Binding Affinity**. This is measured in **kcal/mol**. A more negative value (e.g., -9.0

kcal/mol) indicates a more stable, spontaneous, and stronger interaction, suggesting a higher potential for therapeutic efficacy.

By calculating these energies, the simulation predicts the strength of non-covalent interactions, such as **hydrogen bonds** and **hydrophobic forces**, that anchor Curcumin within the enzyme. [9]

CHAPTER 3: MATERIALS AND METHODS

3.1 Computational Infrastructure and Software Suite

The methodology of this study is grounded in the principles of **Computer-Aided Drug Design (CADD)**. To ensure the accuracy of the molecular docking simulations, a dedicated "Digital Laboratory" was configured. The selection of software was based on their validated accuracy in peer-reviewed pharmaceutical research and their ability to handle complex molecular interactions.

3.1.1 Hardware Specifications

The computational experiments were performed on a high-performance workstation to ensure that the docking algorithms could run with maximum "exhaustiveness" (the depth of the search).

- **System:** ASUS Vivobook
- **Processor:** 13th Gen Intel® Core™ i5-13420H, 2100 Mhz, 8 Core(s)
- **Memory:** 16 GB DDR4 RAM.
- **Operating System:** Windows 11 (64-bit).

3.1.2 Software Specifications and Roles

Each software tool used in this thesis plays a specific role in the "Drug Discovery Pipeline," moving from raw data to a visualized molecular complex.



Fig 9. The Virtual Screening and Molecular Docking Pipeline

1. **RCSB Protein Data Bank (PDB):** This is the global repository where the 3D structure of the **Human COX-2 (5IKR)** was sourced. It provides the "X-ray Crystallography" data required for the experiment.
2. **PubChem Database:** Used as the official source for the **Curcumin** molecule. It provides the validated chemical structure, ensuring the bond lengths and angles are scientifically accurate.
3. **BIOVIA Discovery Studio Visualizer:** This is the "Microscope" of our study. It was used to "clean" the protein by removing unwanted water molecules and existing drugs that were stuck to the protein during the crystal-growing process. It was also used to view the final results in 3D.
4. **Open Babel (GUI):** Often called the "Universal Translator" of chemistry. Since different programs use different "languages" (file formats), Open Babel was used to convert Curcumin from an .sdf file into a .pdbqt file so that the docking engine could read it.
5. **AutoDock Vina:** This is the core "Engine" or the "Mathematical Brain" of the project. It performs the actual docking by calculating the "Binding Affinity." It tries thousands of ways to fit Curcumin into COX-2 and tells us which one is the strongest.
6. **SwissADME (Online Server):** Used to perform "Pharmacokinetic Profiling." This tool tells us if Curcumin can actually be absorbed by the human body as a pill (Drug-likeness) or if it will be filtered out too quickly. [10]

3.2 Preparation of the Receptor (The Lock)

The 3D coordinates of Human COX-2 were obtained from the RCSB Protein Data Bank (PDB ID: 5IKR). The raw protein structure, as obtained from X-ray crystallography, contains several components that are not required for a docking simulation and must be meticulously removed to ensure a clean "Apo-protein" environment.

The preparation was conducted using the following specialized protocol:

- **Removal of Solvent and Co-factors:** All crystallographic water molecules and heteroatoms (non-protein residues) were deleted. This prevents artificial steric hindrance and allows the ligand to access the true active site.
- **Protonation:** Polar hydrogen atoms were added to the structure. This is a critical step because hydrogens are essential for identifying the hydrogen-bonding network between Curcumin and the enzyme.
- **Active Site Emptying:** The co-crystallized ligand (Mefenamic Acid) was extracted from the catalytic pocket to provide an empty space for the new docking pose.

3.2.1 Visual Results of Receptor Refinement

- **(A) Initial Structure:** The raw PDB file containing the protein dimer, co-crystallized ligands, and the crystallographic water shell (red spheres).



- **(B) Dehydrated State:** Successful removal of all water molecules to clear the binding channel.



- **(C) Prepared Apo-receptor:** Final state after extraction of all co-crystallized ligand groups (Ligands 1-12) and heteroatoms, leaving an empty active site for Curcumin docking.



3.3 Preparation of the Ligand (The Key)

The ligand selected for this study is **Curcumin**, a natural polyphenol. For accurate molecular docking, the ligand must be retrieved from a validated chemical database and optimized to its most stable three-dimensional form.

The preparation followed these steps:

- **Retrieval:** The 3D structure of Curcumin (PubChem CID: 969516) was downloaded in Structure Data File (SDF) format. Using a 3D structure is vital to ensure that the initial bond angles and lengths are biologically realistic.
- **Standardization:** The molecule was imported into the visualization environment where **Polar Hydrogens** were added. This step is essential to account for the hydroxyl (-OH) groups on the phenolic rings, which are the primary sites for hydrogen bonding with the COX-2 enzyme.
- **Energy Minimization:** The structure was verified for correct bond orders and valency to ensure that the docking algorithm calculates the most stable "pose" without chemical errors.

A) Screenshot 3.3.1 : The PubChem page showing Curcumin's structure and CID (969516).



B) Screenshot 3.3.2 : 3D Visualization and Protonation of Curcumin (CID: 969516)



3.4 Grid Box Generation and Active Site Identification

Active site identification is a prerequisite for "site-directed" molecular docking. Rather than performing a "blind dock" over the entire protein surface, a specific **Grid Box** was defined to restrict the search to the catalytic pocket of the COX-2 enzyme.

The parameters for the grid box were established as follows:

- **Targeting the Hydrophobic Channel:** The grid was centered on the coordinates previously occupied by the co-crystallized inhibitor in the 5IKR structure. This ensures that Curcumin is docked into the same region where traditional NSAIDs exert their pharmacological effect.
- **Dimensions:** The box size was set to [Insert your X, Y, Z dimensions, e.g., 20Å x 20Å x 20Å]. This volume is large enough to allow Curcumin to rotate freely and explore all possible binding conformations (poses) while remaining confined to the active site.
- **Exhaustiveness:** By defining this search space, the AutoDock Vina algorithm can focus its computational power on calculating the most accurate binding affinities (Delta G) within the biologically relevant region of the enzyme.



Figure 3.4 : Initialization of the Receptor-Ligand Interaction Workspace.

Interpretation: This figure illustrates the transition into the "Site-Directed" docking workflow. By opening the "Define and Edit Binding Site" module, the study prepares to move away from a global search toward a localized, high-precision simulation. This ensures that the computational resources are focused exclusively on the catalytic pocket of the COX-2 enzyme.

3.4.1 Validation of Receptor Binding Pockets

During the identification of the binding site, the protein scaffold was scanned for internal cavities. A valence check was performed to ensure the structural integrity of the amino acid residues within the catalytic domain. While minor valence inconsistencies are common in X-ray crystal structures due to the static nature of the data, the primary focus remained on defining a search space that encompasses the **Hydrophobic Channel** of COX-2.

By utilizing the **Cavity Method**, we successfully mapped the empty volume where the original ligand (Mefenamic Acid) resided. This volume defines our **Grid Box**, providing the mathematical boundaries for the AutoDock Vina search algorithm.



Figure 3.4.1: Structural Integrity and Valence Verification.

Interpretation: The presence of the structural alert in Figure 3.4.1 indicates a rigorous valence check performed by Discovery Studio. In X-ray crystallography structures like 5IKR, minor valence inconsistencies are anticipated due to the lack of hydrogen data in the original PDB file. By acknowledging and validating these parameters, we ensure that the receptor scaffold is optimized for a realistic simulation of non-covalent bonding.

3.4.2 Binding Site Mapping and Coordinate Extraction

The identified receptor cavity (Figure 3.4) was mapped to define the search space for the docking algorithm. This sphere encapsulates the primary catalytic pocket of the COX-2 enzyme, specifically targeting the region where Curcumin can interact with key residues like **Ser530** and **Tyr385**.

The extraction of the (x, y, z) coordinates from this cavity allows for the creation of a precise **Grid Box**. By restricting the search to this volume, we increase the "exhaustiveness" of the docking simulation, ensuring that the software calculates the most stable binding pose with high mathematical accuracy. This approach differentiates "Site-Directed" docking from "Blind" docking, resulting in more biologically relevant data.



Figure 3.4.2: Identification of the Catalytic Cavity using the Mesh Method.

Interpretation: Figure 3.4.2 visually represents the "Search Space" for Curcumin. The green mesh defines the internal volume of the hydrophobic channel. This localized mapping is critical; it proves that the docking search will be confined to the specific "lock" where arachidonic acid normally binds, thereby increasing the biological relevance of the predicted binding poses.

3.4.3 Identification of Catalytic Site Coordinates

The successful generation of a site-sphere (Figure 3.4) allowed for the precise mapping of the COX-2 active site. This sphere encompasses the hydrophobic channel where the enzyme normally processes arachidonic acid into prostaglandins.

The following coordinates were extracted for the molecular docking search space:

- **Center X:** 51.21
- **Center Y:** 7.57
- **Center Z:** 64.30
- **Radius:** 21.00 Å

By defining these specific spatial parameters, the study ensures that the **Curcumin** ligand is docked within the biologically relevant domain. This site-specific approach allows for the identification of critical non-covalent interactions with amino acid residues like **Arg120** and **Tyr355**, which are essential for competitive inhibition.



Figure 3.4.3: Extraction of Precise XYZ Spatial Coordinates.

Interpretation: The attribute window in Figure 3.4.4 provides the mathematical "address" for the docking simulation. The center coordinates (51.21, 7.57, 64.30) and the radius of **21.0 Å** are standardized parameters that will be used in the AutoDock Vina configuration. This ensures that the docking process is repeatable and that the grid box is large enough to accommodate the long-chain structure of the Curcumin molecule.

3.5 Format Conversion and Force Field Application

The transition from structural modeling to computational simulation requires the conversion of molecular data into a specialized format recognized by the AutoDock Vina engine. Using the **Open Babel GUI**, both the macromolecule and the ligand were converted from the standard Protein Data Bank (.pdb) format to the **.pdbqt** format.

This conversion is a critical computational prerequisite that adds two vital layers of data to the structural coordinates:

- **Partial Charges (q):** Gasteiger partial charges were assigned to each atom. This allows the software to calculate the electrostatic attraction and repulsion between Curcumin and the COX-2 residues.
- **Atom Types (t):** Atoms were categorized according to the **AutoDock Force Field**, defining their Van der Waals radii and hydrogen-bonding capabilities.
- **Torsional Detection:** The software identified the rotatable bonds within the Curcumin structure, allowing for flexible docking during the simulation. [11]



Figure 3.5: Conversion of Molecular Files using Open Babel GUI.

Interpretation: Figure 3.5 illustrates the successful processing of the Curcumin ligand. The output terminal confirms the identification of **12 active torsions**, indicating that the ligand maintains its full rotational flexibility for the docking search. The assignment of partial charges and atom types ensures that the subsequent docking results are energetically accurate and physically realistic, mimicking the dynamic behavior of a drug molecule within a biological system.

3.6 Configuration of Docking Parameters

The final stage of the methodology involves the configuration of the AutoDock Vina search engine. A configuration file (conf.txt) was authored to define the spatial boundaries and computational intensity of the simulation. The following parameters were standardized for the study:

- **Grid Box Dimensions:** A search space of **20 x 20 x 20 Å** was established. This volume ensures that the long-chain structure of Curcumin has sufficient room to explore multiple conformational states within the COX-2 active site.
- **Search Exhaustiveness:** The exhaustiveness parameter was set to **8**, providing a balance between computational speed and a thorough search of the ligand's "energy landscape."

- **Scoring Function:** AutoDock Vina utilizes a sophisticated scoring function that combines knowledge-based potentials and empirical force field components to predict the **Gibbs Free Energy** of the binding.



Figure 3.6: Standardized Configuration Profile for Molecular Docking.

Interpretation: Figure 3.6 showcases the finalized mathematical constraints for the docking simulation. By defining the exact center coordinates ($51.21, 7.57, 64.30$) and the search volume, the project ensures a **"Site-Directed"** docking approach. This configuration acts as the blueprint for the AutoDock Vina engine, ensuring that the computational search for Curcumin's binding pose is restricted to the biologically active hydrophobic channel of the COX-2 enzyme.

3.7 Execution of Virtual Screening

Following the parameter configuration, the simulation was initiated via the Command-Line Interface (CLI). This stage represents the transition from preparation to data acquisition.

- **Command Initialization:** The Vina engine was called using the specific configuration flags to synchronize the receptor and ligand data.
- **Algorithmic Search:** The software performed a stochastic global search, iterating through millions of possible orientations to identify the "Global Minimum" energy state.



Figure 3.7.1: Initialization of the AutoDock Vina Search Engine.



Figure 3.7.2: Completion of Simulation and Data Generation.

Interpretation: Figures 3.7.1 and 3.7.2 document the successful execution of the docking algorithm. Figure 3.7.1 confirms that the engine correctly initialized the search space and recognized the structural files. Figure 3.7.2 illustrates the completion of the simulation, resulting in a ranked list of binding affinities. This successful run validates the computational workflow and provides the raw thermodynamic data required for the Results analysis in Chapter 4.

3.8 Pharmacokinetic and Toxicological (ADMET) Profiling

While high-affinity receptor binding within the COX-2 active site is a fundamental prerequisite for anti-inflammatory efficacy, a lead compound must also exhibit favorable pharmacokinetic properties to transition into a viable clinical formulation. A significant proportion of active pharmaceutical ingredients (APIs) fail during late-stage development due to poor oral bioavailability or unacceptable systemic toxicity. To rigorously mitigate these risks and validate the drug-likeness of Curcumin, an extensive *in-silico* ADMET profiling protocol was executed.

To maintain stringent analytical standards and ensure computational reproducibility, this profiling was conducted offline utilizing **OSIRIS DataWarrior** (version 5.5.0, developed by Idorsia Pharmaceuticals Ltd.). DataWarrior is an advanced chemoinformatics and data visualization software equipped with sophisticated predictive algorithms that do not rely on external web server connectivity.

Computational Protocol for ADMET Profiling:

1. **Ligand Retrieval:** The canonical SMILES string of Curcumin was retrieved from the PubChem compound database.
2. **Environment Initialization:** The offline chemoinformatics platform, OSIRIS DataWarrior (version 5.5.0), was launched and a novel structural matrix was generated.
3. **Topological Rendering:** The SMILES string was imported into the structural column, prompting the software's rendering engine to generate a 2D topological map of the Curcumin molecule.
4. **Physicochemical Parameterization:** The analytical engine was configured to calculate core molecular descriptors to evaluate Lipinski's Rule of Five, specifically capturing Molecular Weight, cLogP, Hydrogen Bond Donors, and Hydrogen Bond Acceptors.
5. **Toxicophore Screening:** The structural fragments of Curcumin were computationally mapped against the software's internal toxicity database to screen for Mutagenic, Tumorigenic, Reproductive, and Irritant risks.
6. **Data Extraction:** The computed values were extracted and tabulated for pharmacological evaluation.

3.8.1 Structural Preparation and Molecular Input The computational workflow was initiated by retrieving the canonical Simplified Molecular-Input Line-Entry System (SMILES) notation of Curcumin (COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O) from the PubChem compound database. This linear code was directly imported into the DataWarrior workspace, prompting the software's rendering engine to translate the string into a two-dimensional molecular topology for structural validation.



Figure 3.8.1: The OSIRIS DataWarrior computational matrix displaying the imported 2D topological structure of the Curcumin ligand prior to algorithmic evaluation

3.8.2 Physicochemical Parameterization (Lipinski's Rule of Five) Following structural confirmation, the software's embedded analytical algorithms were configured to calculate fundamental physicochemical descriptors to evaluate the ligand against Lipinski's Rule of Five (Ro5), the pharmaceutical gold standard for predicting oral absorption. The selected parameters included:

- **Total Molecular Weight (MW):** Calculated based on standard atomic masses to ensure the compound remained below the 500 Da threshold, facilitating efficient passive cellular diffusion.
- **Calculated Partition Coefficient (cLogP):** Computed utilizing an atom-additive method to predict distribution between aqueous phases (blood plasma) and lipid phases (cell membranes).
- **Hydrogen Bond Dynamics:** The exact count of hydrogen bond acceptors and donors was parameterized to predict the molecule's polarity and aqueous solubility.



Figure 3.8.2: Manual configuration of the DataWarrior analytical engine to calculate key physicochemical descriptors and drug-likeness parameters.

3.8.3 Toxicophore Screening Configuration Concurrently, the systemic safety of Curcumin was computationally evaluated. DataWarrior predicts toxicity by fragmenting the target molecule and cross-referencing those substructures against an extensive internal database of known toxicophores. The screening was configured to evaluate four primary localized toxicity risks: Mutagenicity (genetic mutation risk), Tumorigenicity (oncogenesis risk), Reproductive Toxicity (teratogenic risk), and Irritancy (mucosal/cutaneous risk).

Chapter 4: Results and Discussion

4.1 Analysis of Thermodynamic Binding Affinities

The primary outcome of the molecular docking study is the quantification of the binding strength between **Curcumin** and the **COX-2 (5IKR)** enzyme. The results, summarized in **Table 4.1**, are expressed as **Binding Affinity (ΔG)** in **kcal/mol**.

The simulation yielded 9 distinct binding orientations (modes). The "Lead Pose" (Mode 1) demonstrated the highest stability with a binding score of **-6.74 kcal/mol**. This negative value confirms that the interaction is thermodynamically spontaneous, meaning Curcumin naturally "prefers" to sit inside the COX-2 active site rather than remaining free in the surrounding environment.

Table 4.1: Binding Affinity Scores for the Curcumin-COX-2 Complex

Mode	Affinity (kcal/mol)	RMSD Lower Bound	RMSD Upper Bound
1	**-6.74**	**0.000**	**0.000**
2	-6.70	0.408	5.073
3	-6.69	2.087	3.156
4	-6.49	1.590	5.629
5	-6.41	12.610	14.140

4.2 Interpretation of the Lead Pose

The binding affinity of **-6.74 kcal/mol** suggests a moderately strong inhibitory potential. In pharmaceutical terms, this score indicates that Curcumin fits well into the hydrophobic pocket of the enzyme, likely competing with the natural substrate, arachidonic acid.

The small difference in energy between Mode 1 and Mode 2 (only **0.04 kcal/mol**) suggests that Curcumin has multiple "near-optimal" orientations. This geometric flexibility may contribute to its broad-spectrum anti-inflammatory properties, as it can adapt its shape to maintain stability within the catalytic channel.

4.3 Post-Docking Visualization and Interaction Analysis

While the binding affinity provides a quantitative measure of stability, the qualitative analysis of the ligand-protein interface is essential to identify the specific chemical forces driving the inhibition. The lead pose (Mode 1, -6.74 kcal/mol) was analyzed using **BIOVIA Discovery Studio Visualizer** to map the intermolecular interactions.

4.3.1 Analysis of the Catalytic Pocket

The Curcumin molecule was found to be deeply embedded within the hydrophobic channel of the **COX-2 (5IKR)** receptor. The orientation of the ligand allows the phenolic groups and the central dione chain to interact with key residues in the active site. This spatial arrangement effectively blocks the channel, preventing the substrate from reaching the catalytic center of the enzyme.

4.3.2 Mapping of Intermolecular Forces and Residue Analysis

To investigate the chemical basis of the **-6.74 kcal/mol** binding affinity, a 2D interaction mapping protocol was executed. This analysis identifies the specific amino acid residues of the **COX-2 (5IKR)** enzyme that stabilize the Curcumin molecule through non-covalent interactions.

The interaction profile (Figure 4.9) reveals that Curcumin is sequestered within a hydrophobic "cage" formed by the following key residues:

- **Arginine (ARG A:120) and Tyrosine (TYR A:355):** These are considered critical residues for COX-2 inhibition. **ARG120** serves as a primary anchoring point for carboxylate groups in traditional NSAIDs; its proximity to Curcumin suggests a competitive inhibitory mechanism.
- **Leucine (LEU A:93) and Valine (VAL A:89):** These residues engage in **Van der Waals** interactions with the aromatic rings of Curcumin, providing significant thermodynamic stability to the complex.



Figure 4.3.2: 2D Interaction Diagram of Curcumin within the COX-2 Active Site

- **Proline (PRO A:86) and Glutamate (GLU A:524):** These residues contribute to the shape complementarity of the pocket, ensuring that the heptadiene-dione chain of Curcumin remains fixed within the catalytic channel.

Interpretation: Figure 4.3.2 illustrates the "Molecular Fingerprint" of the docking success. The light green spheres represent the Van der Waals forces, which dominate the binding interface. The spatial arrangement of these residues confirms that Curcumin successfully targets the same hydrophobic channel utilized by commercial COX-2 inhibitors.

4.4 Comparative Discussion

The results obtained in this study correlate well with existing pharmacological data on polyphenolic compounds. The binding affinity of **-6.74 kcal/mol** indicates that Curcumin possesses a high probability of spontaneous binding. By interacting with **ARG120 and TYR355**, Curcumin likely obstructs the entry of arachidonic acid into the enzyme's active site, thereby inhibiting the downstream production of pro-inflammatory prostaglandins. This in-silico evidence supports the hypothesis that Curcumin acts as a multi-target anti-inflammatory agent, utilizing its flexible structure to achieve high-affinity binding across the COX-2 catalytic domain.

4.5 ADMET and Drug-Likeness Evaluation The successful transition of Curcumin from an *in-silico* COX-2 inhibitor to a viable therapeutic agent depends heavily on its pharmacokinetic behavior. The computational profiling generated offline via OSIRIS DataWarrior confirms that Curcumin possesses an exceptional balance of drug-likeness and systemic safety



Figure 4.5: Final OSIRIS DataWarrior computational spreadsheet displaying the calculated Lipinski parameters and toxicophore screening results for Curcumin.

Table 4.5: Predicted Physicochemical and Toxicity Profile of Curcumin (via OSIRIS DataWarrior)

Parameter Category	Specific Property	Calculated Value	Lipinski Threshold
Physicochemical	Molecular Weight	368.384 g/mol	< 500 g/mol
	Lipophilicity (cLogP)	2.949	< 5.0
	Hydrogen Bond Donors	2	≤ 5
	Hydrogen Bond Acceptors	6	≤ 10
Drug-Likeness	Lipinski's Rule of Five	Accepted	0 Violations
Toxicity Profile	Mutagenic Risk	None	-
	Tumorigenic Risk	None	-
	Reproductive Effect Risk	None	-
	Irritant Risk	None	-

4.4.1 Interpretation of Physicochemical Profile The offline calculation definitively proves that Curcumin strictly adheres to Lipinski's Rule of Five with zero violations. The exact molecular weight (368.384 g/mol) is well below the 500 Da limit, ensuring efficient passive diffusion across the intestinal epithelium. Furthermore, the calculated partition coefficient (cLogP = 2.949) indicates an optimal lipophilic balance; the molecule is lipophilic enough to penetrate lipid bilayer cell membranes, yet retains sufficient polarity (facilitated by its 6 hydrogen bond acceptors and 2 donors) to remain soluble in aqueous physiological environments. This exact data strongly predicts high oral bioavailability.

4.4.2 Interpretation of Toxicological Profile The safety assessment highlights the profound pharmacological advantage of Curcumin as a natural anti-inflammatory agent. The offline toxicophore screening returned negative alerts ("None") across all evaluated severe endpoints: Mutagenicity, Tumorigenicity, Reproductive Toxicity, and Irritancy. Unlike classical synthetic non-steroidal anti-inflammatory drugs (NSAIDs), which frequently present severe gastrointestinal and cardiovascular toxicity risks upon long-term administration, Curcumin's benign structural profile validates it as a highly safe, biologically tolerated candidate for chronic inflammatory management.

Chapter 5: Conclusion and Future Scope

5.1 Conclusion

The present study successfully executed a comprehensive in-silico evaluation of Curcumin's inhibitory potential against the **Cyclooxygenase-2 (COX-2)** enzyme. By utilizing molecular docking as a primary research tool, the project bridged the gap between traditional herbal pharmacology and modern computational drug design.

The core findings of this research are summarized as follows:

- **Thermodynamic Stability:** The docking simulation revealed a lead binding affinity of **-6.74 kcal/mol**. This significant negative value confirms that the interaction between Curcumin and the 5IKR receptor is thermodynamically favorable and spontaneous.
- **Active Site Localization:** Structural visualization confirmed that Curcumin does not bind randomly but specifically targets the **hydrophobic catalytic channel**. This is the same site where the natural substrate, arachidonic acid, typically binds, suggesting a competitive mechanism of inhibition.
- **Molecular Interactions:** The 2D residue mapping identified a robust network of non-covalent forces. The involvement of **ARG120** and **TYR355** is of particular pharmacological importance, as these residues are conserved across the COX enzyme family and play a pivotal role in the anti-inflammatory response.
- **Structural Adaptability:** The minimal energy variance (0.04 kcal/mol) between the top docking modes suggests that Curcumin possesses high conformational flexibility. This allows the molecule to adapt its orientation within the enzyme's binding pocket to maintain stable inhibition.

In summary, this thesis provides strong computational evidence that Curcumin acts as a potent natural ligand for COX-2. The results justify the continued investigation of Curcumin-based scaffolds in the development of safer, non-steroidal anti-inflammatory agents with reduced gastrointestinal side effects.

5.2 Future Scope

While the current docking study provides a solid theoretical foundation, the following areas are recommended for future research to enhance the drug-development pipeline:

1. **Molecular Dynamics (MD) Simulations:** Future studies should involve MD simulations (e.g., 100 ns duration) to assess the **RMSD (Root Mean Square Deviation)** and stability of the Curcumin-COX-2 complex in a dynamic aqueous environment. This would confirm if the "handshake" remains stable under physiological conditions.
2. **In-Vitro and In-Vivo Correlation:** The computational scores should be validated through **wet-lab experiments**, specifically COX-2 enzyme inhibition assays. Determining the IC_{50} value would allow for a direct correlation between the **-6.74** kcal/mol docking score and biological potency.
3. **Lead Optimization and Synthesis:** Based on the interaction map, medicinal chemistry efforts could focus on synthesizing Curcumin analogs. Adding small polar groups (like fluorine or methoxy groups) at specific positions could potentially increase hydrogen bonding with residues like **GLU524**, further improving the binding affinity.
4. **ADMET Profiling:** Future work should include a comprehensive **Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)** analysis to predict the oral bioavailability and safety profile of Curcumin in humans.

References

[1] R. Medzhitov, "Cellular and Molecular Immunology," *Nature,* vol. 454, no. 7203, p. 428–435, 2008.

[2] A. H. L. a. S. P. Abul K. Abbas, Cellular and Molecular Immunology, Philadelphia, PA: Elsevier, 2021.

[3] D. L. D. a. R. M. G. William L. Smith, "Cyclooxygenases: Structural, Cellular, and Molecular Biology," *Annual Review of Biochemistry,* vol. 69, no. 1, p. 145–182, 2000.

[4] C. J. Hawkey, "COX-2 inhibitors," *The Lancet,* vol. 353, no. 9149, p. 307–314, 1999.

[5] S. P. a. B. B. Aggarwal, "Turmeric, the Golden Spice: From Traditional Medicine to Modern Medicine," *Herbal Medicine: Biomolecular and Clinical Aspects (2nd edition),* vol. 13, p. 263–288, 2011.

[6] G. S. a. P. K. Singh, "Molecular Docking: A Review of Recent Advances and Future Perspectives," *International Journal of Computer Applications,* vol. 121, no. 1, pp. 1-5, 2015.

[7] Y. Y. X. Z. K. Z. S. C. a. Z. D. Yan He, "Curcumin and systemic inflammation: A review of mechanisms and medical implications," *Molecules,* vol. 10, no. 20, p. 18520–18532, 2015.

[8] S. O. H. M. S. V. a. M. G. M. P. Lucido, "Crystal Structure of Human Cyclooxygenase-2 Complexed with the NSAID Mefenamic Acid," *Biochemistry,* 2016.

[9] H. D. J. R. F. a. J. B. Dario Kitchen, "Docking and scoring in virtual screening for drug discovery: methods and applications," *Nature Reviews Drug Discovery,* vol. 3, no. 11, p. 935–949, 2004.

[10] M. B. C. A. J. C. M. T. V. a. G. R. H. N. M. O'Boyle, "Open Babel: An open chemical toolbox," *Journal of Cheminformatics,* vol. 3, no. 1, p. 33, 2011.

[11] M. B. C. A. J. C. M. T. V. a. G. R. H. N. M. O'Boyle, "Open Babel: An open chemical toolbox," *Journal of Cheminformatics,* vol. 3, no. 1, p. 33, 2011.